Biodexa (BDRX) news

PLC Resources Ltd - Geo-spectral survey commences at Abbotts Gold project, WA

PLC Resources Ltd (ASX: PLC) has announced the commencement of a geo-spectral survey at its Abbotts Gold project in Western Australia. The survey is part of the company’s ongoing exploration efforts to identify potential gold-bearing structures within the project area. Geo-spectral surveys utilise…

Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational phase 3 trial in FAP

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has reached a significant milestone in its clinical development program, with the enrollment of 100 patients in its registrational Phase 3 trial for eRapa in the treatment of Familial Adenomatous Polyposis (FAP). This achievement marks a key step forward…

Biodexa Pharmaceuticals - ADS ratio change to 1 ADS per 400 ordinary shares from 1 per 50, effective about October 26, 2026 - SEC filing

Biodexa Pharmaceuticals - files for resale of 2.56 mln ADSs by selling shareholders - SEC filing

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has filed with the U.S. Securities and Exchange Commission (SEC) to register the resale of 2,560,000 American Depositary Shares (ADSs) by selling shareholders, according to a recent SEC filing . The registration is part of the company’s ongoing efforts to…

Biodexa Pharmaceuticals - receives Health Canada approval to expand Phase 3 FAP trial into Canada

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) has announced that it has received regulatory approval from Health Canada to expand its Phase 3 Serenta clinical trial for eRapa into Canada. This development follows the successful activation of the first European site at the University of Bonn in…